Human hepatitis B virus and human immunodeficiency virus (HIV), that causes AIDS, share attributes and possible evolutionary relationships. The specific requirements for inducing effective immunity against hepatitis B and HIV are discussed. Lessons learned in studies of hepatitis B and its vaccine may find application in creating a vaccine against HIV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0264-410x(88)80023-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prophylaxis of HBV reinfection and disease in liver transplanted patients: 2024 update on the role of HBIG and cost-effectiveness evaluation.
Minerva Gastroenterol (Torino)
January 2025
Gastroenterology Department of Emergency and Organ Transplantation, University Hospital Policlinico di Bari, Bari, Italy.
Hepatitis B virus (HBV) infection is a major global health concern, with liver transplantation (LT) serving as a critical treatment for end-stage liver disease caused by HBV. However, the risk of HBV reinfection after LT remains significant, necessitating effective prophylaxis. Today, the combination of hepatitis B immune globulin (HBIG) and high-barrier nucleos(t)ide analogues (NUCs) is the standard of care for preventing HBV recurrence post-LT but concerns about the cost of HBIG and access to high-barrier NUCs have led to a reduction in the use, dose, and duration of HBIG in recent years.
View Article and Find Full Text PDFFrom core to surface: Expanding the donor pool with Hepatitis B Surface antigen positive liver allografts.
Liver Transpl
January 2025
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.
After the curtain was raised, Hepatitis C plays on: Celebrities and Hepatitis C.
Liver Transpl
January 2025
Department of Transplant, Mayo Clinic, Jacksonville, FL.
Acute kidney injury and ANCA positivity in a patient treated with glecaprevir/pibrentasvir: a case report.
Front Med (Lausanne)
January 2025
Department of Pathology, Montefiore Medical Center, Bronx, NY, United States.
Background: Glecaprevir/pibrentasvir is an effective antiviral therapy for hepatitis C virus infection and is generally regarded safe in patients with renal impairment. However, renal complications are a notable, albeit rare, concern.
Case Presentation: We report a case of acute kidney injury in a man in his 50s with chronic hepatitis C virus, chronic obstructive pulmonary disease, morbid obesity, a history of heroin dependence, and untreated type 2 diabetes mellitus.
N-acetylcysteine use in a cocaine-induced liver failure: a case report.
Front Toxicol
January 2025
Laboratoire de Pharmacologie Clinique, Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
Background: Cocaine intoxication and abuse is a worldwide problem that can be the cause of numerous acute medical complications, including severe acute hepatitis. Although these cases are scarce, they are extremely serious and may lead to liver transplantation or death. Management of toxic hepatitis, once the causative agent has been discontinued, is essentially symptomatic, based on clinical and biological monitoring and prevention of complications related to acute hepatitis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!